Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Corey

Showing results (501-510 of 511) with videos related to

Pageof 52
Sort By:
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
Nature Medicine|June 17, 1999
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapyT W Chun, D Engel, S B Mizell, et al.
JAMA|August 4, 1999
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study GroupL Corey, A G Langenberg, R Ashley, et al.
Vaccine|March 3, 2001
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humansT G Evans, M J McElrath, T Matthews, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 1999
Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infectionZ Q Zhang, T Schuler, W Cavert, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
Vaccine|October 27, 2016
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trialT Hertz, M G Logan, M Rolland, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
Pediatrics|August 3, 2001
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infectionsD W Kimberlin, C Y Lin, R F Jacobs, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Pageof 52

Showing results (501-510 of 511) with videos related to

Sort By:
Pageof 52
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
Nature Medicine|June 17, 1999
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapyT W Chun, D Engel, S B Mizell, et al.
JAMA|August 4, 1999
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study GroupL Corey, A G Langenberg, R Ashley, et al.
Vaccine|March 3, 2001
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humansT G Evans, M J McElrath, T Matthews, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 1999
Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infectionZ Q Zhang, T Schuler, W Cavert, et al.
The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.
Vaccine|October 27, 2016
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trialT Hertz, M G Logan, M Rolland, et al.
The Journal of Infectious Diseases|April 11, 2001
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteersR B Belshe, C Stevens, G J Gorse, et al.
Pediatrics|August 3, 2001
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infectionsD W Kimberlin, C Y Lin, R F Jacobs, et al.
The Journal of Infectious Diseases|May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation GroupM L Clements-Mann, K Weinhold, T J Matthews, et al.
Pageof 52